741.92 USD
-12.22 (-1.62%)
741.92 USD
0 (0%)
Taking everything into account, REGN scores 6 out of 10 in our fundamental rating. REGN was compared to 528 industry peers in the Biotechnology industry. REGN gets an excellent profitability rating and is at the same time showing great financial health properties. REGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- REGN had positive earnings in the past year.
- In the past year REGN had a positive cash flow from operations.
- Each year in the past 5 years REGN has been profitable.
- In the past 5 years REGN always reported a positive cash flow from operatings.
1.2 Ratios
- REGN has a Return On Assets of 11.40%. This is amongst the best in the industry. REGN outperforms 94.32% of its industry peers.
- With an excellent Return On Equity value of 14.79%, REGN belongs to the best of the industry, outperforming 94.70% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 8.69%, REGN belongs to the top of the industry, outperforming 94.32% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for REGN is significantly below the industry average of 18.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
- With an excellent Profit Margin value of 32.13%, REGN belongs to the best of the industry, outperforming 96.40% of the companies in the same industry.
- REGN's Profit Margin has improved in the last couple of years.
- REGN's Operating Margin of 27.61% is amongst the best of the industry. REGN outperforms 96.40% of its industry peers.
- In the last couple of years the Operating Margin of REGN has declined.
- The Gross Margin of REGN (86.28%) is better than 88.83% of its industry peers.
- In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
- REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for REGN remains at a similar level compared to 1 year ago.
- The number of shares outstanding for REGN has been reduced compared to 5 years ago.
- The debt/assets ratio for REGN has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 7.47 indicates that REGN is not in any danger for bankruptcy at the moment.
- REGN's Altman-Z score of 7.47 is fine compared to the rest of the industry. REGN outperforms 77.46% of its industry peers.
- The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
- REGN has a better Debt to FCF ratio (0.70) than 94.70% of its industry peers.
- REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- REGN's Debt to Equity ratio of 0.09 is on the low side compared to the rest of the industry. REGN is outperformed by 61.74% of its industry peers.
- Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.47 |
ROIC/WACC1.02
WACC8.55%
2.3 Liquidity
- REGN has a Current Ratio of 4.06. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
- REGN has a Current ratio (4.06) which is comparable to the rest of the industry.
- REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of REGN (3.51) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
- REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
- Measured over the past years, REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
- Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
- Measured over the past years, REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
- The Earnings Per Share is expected to grow by 7.62% on average over the next years.
- Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 6.08% on average per year.
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y7.62%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y6.08%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- REGN is valuated correctly with a Price/Earnings ratio of 16.48.
- Compared to the rest of the industry, the Price/Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.27% of the companies listed in the same industry.
- REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.54.
- The Price/Forward Earnings ratio is 16.11, which indicates a correct valuation of REGN.
- 95.08% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of REGN to the average of the S&P500 Index (24.31), we can say REGN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.48 | ||
| Fwd PE | 16.11 |
4.2 Price Multiples
- 94.70% of the companies in the same industry are more expensive than REGN, based on the Enterprise Value to EBITDA ratio.
- 95.45% of the companies in the same industry are more expensive than REGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.09 | ||
| EV/EBITDA | 15.16 |
4.3 Compensation for Growth
- The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.26
EPS Next 2Y0.46%
EPS Next 3Y6.66%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.44%, REGN is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 1.26, REGN pays a better dividend. On top of this REGN pays more dividend than 98.30% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.92, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.44% |
5.2 History
- REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y0.46%
EPS Next 3Y6.66%
741.92
-12.22 (-1.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/bmo
Earnings (Next)01-30 2026-01-30/amc
Inst Owners90.13%
Inst Owner Change-0.04%
Ins Owners1.95%
Ins Owner Change3.45%
Market Cap77.98B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts79.44
Price Target808.25 (8.94%)
Short Float %2.71%
Short Ratio2.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.44% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)1.54%
PT rev (3m)8.5%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)16.02%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)4.37%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)2.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.48 | ||
| Fwd PE | 16.11 | ||
| P/S | 5.47 | ||
| P/FCF | 20.09 | ||
| P/OCF | 15.38 | ||
| P/B | 2.52 | ||
| P/tB | 2.64 | ||
| EV/EBITDA | 15.16 |
EPS(TTM)45.01
EY6.07%
EPS(NY)46.06
Fwd EY6.21%
FCF(TTM)36.93
FCFY4.98%
OCF(TTM)48.25
OCFY6.5%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)N/A
PEG (5Y)1.26
Graham Number546.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.47 |
F-Score5
WACC8.55%
ROIC/WACC1.02
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y7.62%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y6.08%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-5.21%
EBIT Next 3Y6.05%
EBIT Next 5Y11.85%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?
The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.